0001193125-13-233105.txt : 20130628 0001193125-13-233105.hdr.sgml : 20130628 20130523141126 ACCESSION NUMBER: 0001193125-13-233105 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 430 CITY: BROOMFIELD STATE: CO ZIP: 80021 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 430 CITY: BROOMFIELD STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 CORRESP 1 filename1.htm CORRESP

May 23, 2013

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Re: ARCA biopharma, Inc.

Registration Statement on Form S-1

Filed: March 25, 2013

File No. 333-187508

Ladies and Gentlemen:

Effective immediately, the undersigned withdraw the request for acceleration sent to your office via EDGAR on May 16, 2013, which requested that the Commission take appropriate action to cause the above-referenced Registration Statement to become effective at 4:00 p.m. Eastern Time on May 20, 2013 or as soon thereafter as practicable. The undersigned anticipate filing an additional acceleration request in the near future.

Sincerely,

ARCA BIOPHARMA, INC.

 

By:  

/s/ Patrick M. Wheeler

  Patrick M. Wheeler
  Chief Financial Officer

 

cc: Jeffrey Riedler, Assistant Director, SEC

Austin Stephenson, Esq., SEC

Daniel Greenspan, Esq., SEC

Brent D. Fassett, Esq., Cooley LLP